Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonate therapy for severe osteogenesis imperfecta.

F H Glorieux1

  • 1Department of Surgery, McGill University and Shriners Hospital, Montreal, Quebec, Canada. glorieux@shriners.mcgill.ca

Journal of Pediatric Endocrinology & Metabolism : JPEM
|November 22, 2000
PubMed
Summary

Pamidronate treatment significantly improves bone mineral density and reduces fractures in children with severe Osteogenesis Imperfecta (OI). This therapy enhances mobility and pain relief without affecting growth or healing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cortical bone material / compositional properties in growing children and young adults aged 1.5-23 years, as a function of gender, age, metabolic activity, and growth spurt.

Bone·2022
Same author

Perspectives on the evolution of genetic counselling: Experience over three decades in a family with recurrent lethal osteogenesis imperfecta.

Molecular genetics and metabolism·2020
Same author

Genotype and malocclusion in patients with osteogenesis imperfecta.

Orthodontics & craniofacial research·2018
Same author

Long-term follow-up in osteogenesis imperfecta type VI.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016

Area of Science:

  • Pediatric Endocrinology
  • Bone Metabolism
  • Genetic Connective Tissue Disorders

Background:

  • Osteogenesis Imperfecta (OI) is a group of genetic disorders primarily affecting type I collagen.
  • Severe OI in children leads to recurrent fractures, deformities, and mobility issues.

Purpose of the Study:

  • To evaluate the efficacy of cyclical intravenous pamidronate in managing severe Osteogenesis Imperfecta in children.
  • To assess the impact of pamidronate on bone mineral density, fracture incidence, and clinical outcomes.

Main Methods:

  • Cyclical intravenous administration of pamidronate was given to children with severe OI.
  • Evaluated changes in bone mineral density, fracture rates, growth, pain, and fatigue.

Main Results:

Related Experiment Videos

  • Pamidronate increased bone mineral density and decreased fracture incidence.
  • Reduced dependence on mobility aids, with significant relief from chronic pain and fatigue.
  • No adverse effects on fracture healing, growth rate, or growth plates were observed.

Conclusions:

  • Pamidronate is the first therapy to significantly alter the natural course of severe OI.
  • It improves clinical status and quality of life in affected children.
  • While not addressing the underlying collagen defect, it offers substantial therapeutic benefits.